Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing targeted cancer immunotherapies. Co.'s product candidates are being developed in the field of immuno-oncology. Co.'s main candidate, AFM13, is an innate cell engager designed for the treatment of certain CD30-positive malignancies including T cell lymphomas. Co.'s second candidate, AFM24, is a tetravalent, bispecific epidermal growth factor receptor (EGFR)- and CD16A-binding innate cell engager. AFM24 is designed to address limitations, such as toxicities or treatment resistance, associated with existing therapeutic anti-EGFR monoclonal antibodies. The AFMD stock yearly return is shown above.
The yearly return on the AFMD stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AFMD annual return calculation with any dividends reinvested as applicable (on ex-dates).
|